Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NetEase

Otter Tail

Rollins

Tap top-ranked Otter Tail (OTTR), Rollins (ROL), DaVita (DVA) and NetEase (NTES) -- that come from top-ranked sectors too -- should realize the ongoing Fed-induced Santa Claus rally in 2023.

Santa Claus Rally Sets In: 4 Stocks From Top Sectors to Play

Legalzoom.com

MPTI, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 20, 2023.

Best Growth Stocks to Buy for December 20th

Funding to support co-created 'Start Early' program aimed at increasing degree completion rates  DENVER , Dec. 19, 2023 /PRNewswire/ -- The DaVita Giving Foundation has awarded Western Governors University's (WGU) Michael O. Leavitt School of Health (LSH) a $1 million grant over the next three years to support more than 1,500 nursing students in Start Early , a program co-created by DaVita Inc. and WGU to help increase nursing degree completion at the university nationwide.

DaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students

Brinker International

Everest Group Ltd

DVA, EAT and EG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 18, 2023.

Best Growth Stocks to Buy for December 18th

DocuSign

Duolingo

Palantir Technologies

Vertiv Holdings Co

We have narrowed our search to five growth stocks that have solid upside left for the rest of 2023. These are: DOCU, DUOL, DVA, VRT, PLTR.

5 Top Growth Stocks to Make the Most of Santa Claus Rally

Comcast

Molson Coors Brewing

Investors seeking to tap the bullish momentum in the S&P 500 should invest in undervalued stocks like Everest Group (EG), Comcast (CMCSA), 3M Company (MMM), Molson Coors (TAP) and DaVita (DVA).

5 Undervalued S&P 500 Stocks to Buy for 2024

Griffon

GFF, DVA and EG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 12, 2023.

Best Growth Stocks to Buy for December 12th

SPDR S&P 500 ETF Trust

Many stocks in the S&P 500 ETF may be undervalued and have the potential to rise toward their peak values.

5 Undervalued Stocks in the S&P 500 ETF to Buy for 2024

Chemed

Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both DaVita HealthCare (DVA) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?

DVA or CHE: Which Is the Better Value Stock Right Now?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

DaVita HealthCare (DVA) Up 22.8% Since Last Earnings Report: Can It Continue?

Assurant

EMCOR Group

XPO Logistics

We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, XPO, AIZ, EME, DUOL.

Top 5 Mid-Cap Stocks Likely to Turn Large-Cap in 2024

Barrett Business Services

EGHT, DVA and BBSI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 7, 2023.

Best Growth Stocks to Buy for December 7th

Limbach Holdings

Park Hotels & Resorts

LMB, DVA and PK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 5, 2023.

Best Growth Stocks to Buy for December 5th

Cboe Global Markets

Intel

Gartner

Royal Caribbean Cruises

Five S&P 500 stocks with more potential are: IT, INTC, RCL, CBOE, DVA.

Top 5 High-Flying S&P 500 Stocks of November With More Upside

Since 2007, DaVita has raised millions and impacted thousands globally through annual activity-based events DENVER , Nov. 30, 2023 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced the success of its 2023 Move It With Purpose (MIWP) event. MIWP is an annual community-driven initiative that brings together DaVita teammates, friends, family members, and the kidney care community to support Bridge of Life, a nonprofit founded by DaVita to support the prevention and treatment of chronic disease.

DaVita's 'Move It With Purpose' Event Achieves Record-Breaking Participation to Support Life-Saving Care

TopBuild

Twenty-First Century Fox

Itron

Leidos Hld

Here are five stocks that match our screening criteria ??? FOXA, DVA, LDOS, BLD and ITRI.

5 Finest PEG-Based Value Stocks to Buy Now

Advanced Micro Devices

Axon Enterprise

Despite the fear and concern that bear markets create, smart investors understand they are excellent buying opportunities. We don't know when they'll hit, how far they'll fall or how long they will last, but decades of data show the memory of every previous bear market was wiped clean by a bull market.

Only Have $100? 3 No-Brainer Stocks to Buy Right Now

Addus HomeCare

Option Care Health

Pennant Group Inc

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.

4 Stocks to Watch in an Evolving Outpatient Home Health Industry

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Why You Should Add DaVita (DVA) Stock to Your Portfolio

Modiv

MDV, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 16, 2023.

Best Growth Stocks to Buy for November 16th

DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About DaVita HealthCare (DVA) Rating Upgrade to Strong Buy

The consensus price target hints at a 33.2% upside potential for DaVita HealthCare (DVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does DaVita HealthCare (DVA) Have the Potential to Rally 33.24% as Wall Street Analysts Expect?

Alkermes

Amphastar Pharma

Ginkgo Bioworks Holdings

Jazz Pharmaceuticals

OraSure Technologies

United Therapeutics

If you're a fan of the hit TV show Shark Tank, you've probably come across the intriguing term “unicorn” companies. Indeed, these fantastical entities are not only confined to the realm of imagination.

7 Healthcare Stocks That Are Poised to Become the Next Unicorns

DaVita's (DVA) robust segmental revenues drive its third-quarter performance.

DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up

DaVita Inc. (DVA) Q3 2023 Earnings Call Transcript

News for DaVita Stock (DVA)